Endocrinology

The class of GLP-1 receptor agonists and similar agents, originally approved to treat type 2 diabetes, also reduce body weight and reduce CVD risk; what's next?

Women with an evening vs morning chronotype were 54% more likely to have unhealthy lifestyles that in turn accounted for a significant increased risk for diabetes.

The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.

A daily dose of clinical news on Patient Care you may have missed.

Reduction in levels of 4 biomarkers was correlated with lower risk of composite cardiorenal outcomes in the CREDENCE trial, suggesting use of the panel to augment current risk assessment tools.

A daily dose of clinical news on Patient Care you may have missed.

More than 90 million adults in the US with overweight/obesity are candidates for weight loss treatment with semaglutide 2.4 mg, according to a new study.

The newly named centers across the country will work closely with communities to focus research on populations at greatest risk for perinatal morbidity and mortality.

A daily dose of clinical news on Patient Care you may have missed.

Patients with diabetes will be able to save money when ordering insulin and commonly prescribed products, such as continuous glucose monitors and pumps.

A post hoc analysis of the landmark SOLOIST-WFH trial supports avoiding delay in initiating the SGLT-2/1 inhibitor as part of guideline-recommended treatment.

A daily dose of clinical news on Patient Care you may have missed.

A daily dose of clinical news on Patient Care you may have missed.

The new policy is helping people who are taking insulin save money and helping others to afford it in the first place, says a study coauthor from the USC Sol Price School of Public Policy .

In adults with obesity or overweight plus comorbidities but without T2D once-weekly tirzepatide was associated with significant and durable weight loss vs placebo.

Reductions in LDL-C, HbA1c, and body weight were associated with a variety of vegetarian diets in participants with or at high risk for cardiovascular disease.

Methods proven to prevent ASCVD may fall short in certain populations if the impacts of SDOH are not closely monitored. The ACC/AHA provide considerations for 7 health domains.

Since 2014, the age-adjusted mortality rate for diabetes and CVD has increased by 1% after an overall decline between 1999 and 2019, new research finds.

Guidelines on primary ASCVD prevention from the USPSTF and the AHA/ACC/Multisociety differ on why and when to initiate a statin. Try the 5-question quiz.

Your daily dose of clinical news you may have missed.

AspyreRx™, prescribed in 90-day increments, resulted in a mean HbA1c reduction of 1.3% at 180 days in 1 out of 2 phase 3 trial participants. A Q4 launch is anticipated.

Your daily dose of clinical news you may have missed.

Is BMI or body fat a better estimate of obesity?; spoiler: older women do drink ETOH; USPSTF vs ACC/AHA; plus no more opioids for LBP and a primer on migraine meds.

In Israel, where 60% of adults are overweight, new research prompts investigators to suggest that % body fat should replace BMI as the gold standard measure of obesity.

Binge drinking among women going through menopause has been on the rise, research indicates, making clinical inquiry in this population particularly important.

In patients with NAFLD, type 2 diabetes was found to be an independent predictor of both hepatic decompensation and incident HCC, according to meta-analysis authors. .

The importance of avoiding judgement, monitoring behavior, and cardiovascular risk prevention in primary care are discussed, here.

The expanded indication widens the patient population eligible for the novel siRNA therapy to include high-risk patients on maximum statin Rx who have not had a CV event.

In a study of over 26 000 participants, statin use was associated with reduced risk for all-cause and CV mortality compared to placebo.

Your daily dose of clinical news you may have missed.